(Q83781799)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

main subject

Neisseria meningitidis

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Bas van de Waterbeemd

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Lonneke van Keulen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Jan van den Ijssel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Alex de Haan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Michel H Eppink

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Leo A van der Pol

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

30 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

3683-3690

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

A review of vaccine research and development: meningococcal disease

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Development of vaccines against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Challenges and progress in the development of a serogroup B meningococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Biogenesis of bacterial membrane vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Release of outer membrane fragments from normally growing Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Structure of the OmpA-like domain of RmpM from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

EDTA-induced membrane fluidization and destabilization: biophysical studies on artificial lipid membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Effect of chelating agents on the susceptibility of some strains of gram-negative bacteria to some antibacterial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Effect of ethylenediaminetetraacetic acid and related chelating agents on whole cells of gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Assessment of the manufacturability of Escherichia coli high cell density fermentations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Quality by design for biopharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Roadmap for implementation of quality by design (QbD) for biotechnology products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Modeling Neisseria meningitidis B metabolism at different specific growth rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Meningococcal surrogates of protection--serum bactericidal antibody activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Scale-up for bulk production of vaccine against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Outer membrane vesicles of Lysobacter sp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

An extracellular glycolipid produced by Escherichia coli grown under lysine-limiting conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Synthesis and assembly of bacterial membrane components. A lipopolysaccharide-phospholipid-protein complex excreted by living bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Combined in-fermenter extraction and cross-flow microfiltration for improved inclusion body processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Heat-induced blebbing and vesiculation of the outer membrane of Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

Isolation and Characterization of a Native Cell Wall Complex from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.03.028

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.03.028

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22464965%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference